A detailed history of Wells Fargo & Company transactions in Immix Biopharma, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 330 shares of IMMX stock, worth $716. This represents 0.0% of its overall portfolio holdings.

Number of Shares
330
Previous 330 -0.0%
Holding current value
$716
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.81 - $3.06 $188 - $318
-104 Reduced 23.96%
330 $0
Q1 2024

May 10, 2024

BUY
$2.64 - $6.68 $113 - $287
43 Added 11.0%
434 $1,000
Q4 2023

Feb 09, 2024

BUY
$2.82 - $7.27 $941 - $2,428
334 Added 585.96%
391 $2,000
Q3 2023

Nov 13, 2023

BUY
$1.63 - $3.68 $24 - $55
15 Added 35.71%
57 $0
Q2 2023

Aug 15, 2023

BUY
$1.6 - $2.9 $6 - $11
4 Added 10.53%
42 $0
Q1 2023

May 12, 2023

BUY
$1.72 - $3.14 $1 - $3
1 Added 2.7%
38 $0
Q4 2022

Feb 13, 2023

BUY
$0.75 - $2.43 $0 - $2
1 Added 2.78%
37 $0
Q3 2022

Nov 14, 2022

SELL
$1.36 - $3.05 $46 - $103
-34 Reduced 48.57%
36 $0
Q2 2022

Aug 12, 2022

BUY
$1.3 - $2.97 $57 - $130
44 Added 169.23%
70 $0
Q1 2022

May 16, 2022

BUY
$1.86 - $6.75 $48 - $175
26 New
26 $0

Others Institutions Holding IMMX

About Immix Biopharma, Inc.


  • Ticker IMMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,910,100
  • Market Cap $30.2M
  • Description
  • Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specif...
More about IMMX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.